{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:48:34Z","timestamp":1775609314174,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T00:00:00Z","timestamp":1667692800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008327","name":"Zhejiang Institute of Technology","doi-asserted-by":"publisher","award":["2015128660"],"award-info":[{"award-number":["2015128660"]}],"id":[{"id":"10.13039\/501100008327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.heliyon.2022.e11530","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T10:34:50Z","timestamp":1668162890000},"page":"e11530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Closing gaps in medication taking for secondary prevention of coronary heart disease patients among US adults"],"prefix":"10.1016","volume":"8","author":[{"given":"Xiaowei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2022.e11530_bib1","first-page":"e6","article-title":"Heart disease and stroke statistics--2013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.heliyon.2022.e11530_bib2","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American heart association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.heliyon.2022.e11530_bib3","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.cir.0000436752.99896.22","article-title":"Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association","volume":"128","author":"Fleg","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.heliyon.2022.e11530_bib4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11886-014-0486-3","article-title":"The global burden of cardiovascular diseases: a challenge to improve","volume":"16","author":"Mendis","year":"2014","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.heliyon.2022.e11530_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2021.01.005","article-title":"Closing gaps in lifestyle adherence for secondary prevention of coronary heart disease","volume":"145","author":"Aggarwal","year":"2021","journal-title":"Am. J. Cardiol."},{"issue":"9326","key":"10.1016\/j.heliyon.2022.e11530_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0140-6736(02)09358-3","article-title":"Two decades of progress in preventing vascular disease","volume":"360","author":"Yusuf","year":"2002","journal-title":"Lancet"},{"issue":"9753","key":"10.1016\/j.heliyon.2022.e11530_bib7","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.heliyon.2022.e11530_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","article-title":"Beta blockade during and after myocardial infarction: an overview of the randomized trials","volume":"27","author":"Yusuf","year":"1985","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e11530_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"6921","key":"10.1016\/j.heliyon.2022.e11530_bib10","first-page":"81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy--I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","year":"1994","journal-title":"Antiplatelet Trialists' Collaboration"},{"issue":"7404","key":"10.1016\/j.heliyon.2022.e11530_bib11","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","article-title":"A\u00a0strategy to reduce cardiovascular disease by more than 80%","volume":"326","author":"Wald","year":"2003","journal-title":"BMJ"},{"issue":"8478","key":"10.1016\/j.heliyon.2022.e11530_bib12","first-page":"397","article-title":"Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)","volume":"1","year":"1986","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.heliyon.2022.e11530_bib13","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.amjcard.2013.05.064","article-title":"Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and Nutrition Examination Survey 2007-2010)","volume":"112","author":"Tang","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e11530_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/11535240-000000000-00000","article-title":"Extent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005-2006 national survey","volume":"10","author":"Vulic","year":"2010","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"2","key":"10.1016\/j.heliyon.2022.e11530_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","article-title":"EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries","volume":"16","author":"Kotseva","year":"2009","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e11530_bib16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","author":"Bhatt","year":"2006","journal-title":"JAMA"},{"issue":"9798","key":"10.1016\/j.heliyon.2022.e11530_bib17","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.heliyon.2022.e11530_bib18","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1345\/aph.1L700","article-title":"Targeting suboptimal prescribing in the elderly: a review of the impact of pharmacy services","volume":"43","author":"Castelino","year":"2009","journal-title":"Ann. Pharmacother."},{"issue":"5","key":"10.1016\/j.heliyon.2022.e11530_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.amjopharm.2009.11.002","article-title":"Underuse of indicated medications among physically frail older US veterans at the time of hospital discharge: results of a cross-sectional analysis of data from the Geriatric Evaluation and Management Drug Study","volume":"7","author":"Wright","year":"2009","journal-title":"Am. J. Geriatr. Pharmacother."},{"issue":"8","key":"10.1016\/j.heliyon.2022.e11530_bib21","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.amjcard.2013.05.064","article-title":"Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and Nutrition Examination Survey 2007-2010)","volume":"112","author":"Tang","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"22","key":"10.1016\/j.heliyon.2022.e11530_bib22","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American heart association and American College of Cardiology foundation","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"issue":"Supplement_1","key":"10.1016\/j.heliyon.2022.e11530_bib23","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2337\/dc22-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.heliyon.2022.e11530_bib24","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"International society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.heliyon.2022.e11530_bib25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A\u00a0more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann. Intern. Med."},{"issue":"17","key":"10.1016\/j.heliyon.2022.e11530_bib26","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American heart association\/national heart, lung, and blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"25 Suppl 2","key":"10.1016\/j.heliyon.2022.e11530_bib27","first-page":"S102","article-title":"AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American heart association task force on practice guidelines and the obesity society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"issue":"25 Suppl 2","key":"10.1016\/j.heliyon.2022.e11530_bib28","first-page":"S76","article-title":"AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American heart association task force on practice guidelines","volume":"129","author":"Eckel","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.heliyon.2022.e11530_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0002-9459(24)03586-1","article-title":"Antianginal actions of beta-adrenoceptor antagonists","volume":"71","author":"O'Rourke","year":"2007","journal-title":"Am. J. Pharmaceut. Educ."},{"issue":"20","key":"10.1016\/j.heliyon.2022.e11530_bib30","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1001\/jama.1983.03340200048027","article-title":"A\u00a0randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results","volume":"250","year":"1983","journal-title":"JAMA"},{"issue":"9798","key":"10.1016\/j.heliyon.2022.e11530_bib33","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.heliyon.2022.e11530_bib34","first-page":"338","article-title":"Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service Framework","volume":"27","author":"Ramsay","year":"2005","journal-title":"J.\u00a0Public Health"},{"issue":"8","key":"10.1016\/j.heliyon.2022.e11530_bib31","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/hrt.2005.069419","article-title":"Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study","volume":"92","author":"Murphy","year":"2006","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.heliyon.2022.e11530_bib35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9386","key":"10.1016\/j.heliyon.2022.e11530_bib36","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"issue":"9535","key":"10.1016\/j.heliyon.2022.e11530_bib37","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(06)69201-5","article-title":"Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials","volume":"368","author":"Dagenais","year":"2006","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.heliyon.2022.e11530_bib38","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1161\/circ.113.10.e409","volume":"113","author":"Sacco","year":"2006","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.heliyon.2022.e11530_bib39","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.amjcard.2013.05.064","article-title":"Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and Nutrition Examination Survey 2007-2010)","volume":"112","author":"Tang","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.heliyon.2022.e11530_bib32","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/HCR.0000000000000056","article-title":"Intensive nursing care by an electronic followup system to promote secondary prevention after percutaneous coronary intervention: a randomized trial","volume":"34","author":"Hu","year":"2014","journal-title":"J\u00a0Cardiopulm Rehabil Prev"},{"issue":"2","key":"10.1016\/j.heliyon.2022.e11530_bib41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","article-title":"EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries","volume":"16","author":"Kotseva","year":"2009","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e11530_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194081","article-title":"Socioeconomic inequality in medication persistence in primary and secondary prevention of coronary heart disease - a population-wide electronic cohort study","volume":"13","author":"King","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.heliyon.2022.e11530_bib43","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin. Cardiol."},{"issue":"9493","key":"10.1016\/j.heliyon.2022.e11530_bib44","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.heliyon.2022.e11530_bib45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosissup.2004.08.027","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994","volume":"5","author":"Pedersen","year":"2004","journal-title":"Atherosclerosis Suppl."},{"issue":"9255","key":"10.1016\/j.heliyon.2022.e11530_bib46","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0140-6736(00)04042-3","article-title":"Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease","volume":"357","author":"Reid","year":"2001","journal-title":"Lancet"},{"issue":"9326","key":"10.1016\/j.heliyon.2022.e11530_bib47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.heliyon.2022.e11530_bib48","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/hrt.2010.198804","article-title":"The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART)","volume":"96","author":"Jernberg","year":"2010","journal-title":"Heart"},{"issue":"16","key":"10.1016\/j.heliyon.2022.e11530_bib49","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/CIRCULATIONAHA.116.026336","article-title":"Medical therapy for secondary prevention and long-term outcome in patients with myocardial infarction with nonobstructive coronary artery disease","volume":"135","author":"Lindahl","year":"2017","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.heliyon.2022.e11530_bib50","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.heliyon.2022.e11530_bib51","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jacc.2015.10.005","volume":"67","author":"Levine","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e11530_bib52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e11530_bib53","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jama.1997.03540260029031","article-title":"Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction","volume":"277","author":"Soumerai","year":"1997","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.heliyon.2022.e11530_bib54","first-page":"D11","article-title":"Interventions for enhancing medication adherence","author":"Haynes","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"10.1016\/j.heliyon.2022.e11530_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000333","article-title":"Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world","volume":"7","author":"Niens","year":"2010","journal-title":"PLoS Med."},{"issue":"9622","key":"10.1016\/j.heliyon.2022.e11530_bib56","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(08)60623-6","article-title":"Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data","volume":"371","author":"Xavier","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.heliyon.2022.e11530_bib57","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2471\/BLT.10.084327","article-title":"Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries","volume":"89","author":"Cameron","year":"2011","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.heliyon.2022.e11530_bib58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2261-10-25","article-title":"Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO\/HAI data","volume":"10","author":"van Mourik","year":"2010","journal-title":"BMC Cardiovasc. Disord."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022028183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022028183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:03:48Z","timestamp":1775606628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844022028183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2405844022028183"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e11530","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Closing gaps in medication taking for secondary prevention of coronary heart disease patients among US adults","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e11530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e11530"}}